EP3711754A1 - Therapiekombination zur krebsbehandlung enthaltend eine platinverbindung und einen extrakt der spezies nerium - Google Patents

Therapiekombination zur krebsbehandlung enthaltend eine platinverbindung und einen extrakt der spezies nerium Download PDF

Info

Publication number
EP3711754A1
EP3711754A1 EP20159407.4A EP20159407A EP3711754A1 EP 3711754 A1 EP3711754 A1 EP 3711754A1 EP 20159407 A EP20159407 A EP 20159407A EP 3711754 A1 EP3711754 A1 EP 3711754A1
Authority
EP
European Patent Office
Prior art keywords
therapeutic combination
cisplatin
cancer
extract
anvirzel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20159407.4A
Other languages
English (en)
French (fr)
Inventor
Dennis R. Knocke
Joseph B. Nester
Ioannis PAPASOTIRIOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerium Biotechnology Inc
Original Assignee
Nerium Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerium Biotechnology Inc filed Critical Nerium Biotechnology Inc
Publication of EP3711754A1 publication Critical patent/EP3711754A1/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • An embodiment of the invention is a therapeutic combination comprising (I) an anti-neoplastic agent comprising platinum and (II) an extract from a species of the genus Nerium.
  • Another embodiment of the invention is the above therapeutic combination, wherein (II) is an extract from the species Nerium oleander.
  • Another embodiment of the invention is the above therapeutic combination, wherein (II) is a water-based extract.
  • Yet another embodiment of the invention is a method for treating cancer comprising administering to a patient in need thereof a therapeutic combination comprising (I) an anti-neoplastic agent comprising platinum and (II) an extract from a species of the genus Nerium.
  • Another embodiment of the invention is the above method, wherein (II) is an aloe-based extract.
  • the anti-neoplastic agent used in the therapeutic combinations of this invention can be any known anti-cancer or anti-tumor agent or drug that contains platinum.
  • Non-limiting examples include cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin, triplatin, and phosphaplatins, such as those disclosed in U.S. Patent No. 8,034,964 and which are incorporated herein by reference. These compounds can be prepared by methods known in the art.
  • the anti-neoplastic agent is cisplatin.
  • Cisplatin is a divalent inorganic water-soluble, platinum containing complex widely used to treat testicular, bladder, and ovarian cancers.
  • the extract used in this method can be administered intramuscularly, sublingually, or intramuscularly and sublingually, either in a single dose or in multiple doses.
  • the normal dosage for AnvirzelTM is 0.5 to 1.0 mL intramuscularly, 1.0 to 2.0 mL sublingually, or a combination of intramuscular and sublingual administration so that the total amount in a 24 hour period is no greater that 2 mL.
  • AnvirzelTM administered sublingually only is divided into a series of smaller sub-doses, typically two to four doses of 0.5 mL or less per 24 hours.
  • the therapeutic combinations of the invention can be administered to the patient simultaneously, separately, or sequentially.
  • the therapeutic combinations of the invention can be used according to this method to treat any type of cancer.
  • examples include prostate cancer, melanoma, pancreatic cancer, lung cancer, breast cancer, and colorectal cancer.
  • the Methyl Tetrazolium, Sulforhodamine B, and Crystal Violet assays were used to assess cell viabilities. The incubation times were 24 hours, 48 hours, and 72 hours.
  • the Nerium oleander extract AnvirzelTM (a hot water extract of oleander obtained from Salud Integral, Honduras) was tested in concentrations ranging from 0.01 ng/mL to 10 ng/mL.
  • Cisplatin (Sigma, P4394) was tested in concentrations ranging from 0.1 ⁇ g/mL to 100 ⁇ g/mL.
  • Table 2 shows results for A375 cells, a melanoma-derived cell line, with cell population densities estimated from optical absorbance data
  • Table 4 shows results for COLO699N cells, a lung cancer-derived cell line, with cell population densities estimated from optical absorbance data.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
EP20159407.4A 2011-10-20 2012-10-20 Therapiekombination zur krebsbehandlung enthaltend eine platinverbindung und einen extrakt der spezies nerium Withdrawn EP3711754A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549386P 2011-10-20 2011-10-20
PCT/US2012/061226 WO2013059753A1 (en) 2011-10-20 2012-10-20 Therapeutic combination for the treatment of cancer
EP12841023.0A EP2768498B1 (de) 2011-10-20 2012-10-20 Therapiekombination zur krebsbehandlung

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP12841023.0A Division EP2768498B1 (de) 2011-10-20 2012-10-20 Therapiekombination zur krebsbehandlung

Publications (1)

Publication Number Publication Date
EP3711754A1 true EP3711754A1 (de) 2020-09-23

Family

ID=48141445

Family Applications (2)

Application Number Title Priority Date Filing Date
EP12841023.0A Active EP2768498B1 (de) 2011-10-20 2012-10-20 Therapiekombination zur krebsbehandlung
EP20159407.4A Withdrawn EP3711754A1 (de) 2011-10-20 2012-10-20 Therapiekombination zur krebsbehandlung enthaltend eine platinverbindung und einen extrakt der spezies nerium

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP12841023.0A Active EP2768498B1 (de) 2011-10-20 2012-10-20 Therapiekombination zur krebsbehandlung

Country Status (13)

Country Link
US (2) US20130209579A1 (de)
EP (2) EP2768498B1 (de)
JP (1) JP6255346B2 (de)
CN (2) CN104093405A (de)
AU (3) AU2012325819B2 (de)
BR (1) BR112014009421A2 (de)
CA (1) CA2852274C (de)
GT (1) GT201400071A (de)
IL (2) IL231987B (de)
IN (1) IN2014KN00796A (de)
MX (2) MX365635B (de)
RU (2) RU2017136415A (de)
WO (1) WO2013059753A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009303460B9 (en) * 2008-10-14 2014-12-18 Nerium Biotechnology, Inc. Process for extracting cardiac glycodides and compositions
WO2016172393A1 (en) * 2015-04-22 2016-10-27 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
WO2017060661A1 (en) * 2015-10-05 2017-04-13 Nucana Biomed Limited Combination therapy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135745A (en) 1986-05-13 1992-08-04 Ozel Huseyin Z Extracts of nerium species, methods of preparation, and use therefore
US6565897B2 (en) 1998-09-24 2003-05-20 Ozelle Pharmaceuticals, Inc. Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof
US20070154573A1 (en) 2005-12-27 2007-07-05 Juay Jamil Rashan Method of preparing and using a cold extract from the leaves of nerium oleander
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US20100092585A1 (en) 2008-10-14 2010-04-15 Nerium Biotechnology, Inc. Plant extraction method and compositions
US8034964B2 (en) 2007-08-06 2011-10-11 Ohio University Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407675B2 (en) * 2002-12-27 2008-08-05 The Trustees Of Columbia University In The City Of New York Anti-neoplastic compositions comprising extracts of black cohosh
US20060205679A1 (en) * 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135745A (en) 1986-05-13 1992-08-04 Ozel Huseyin Z Extracts of nerium species, methods of preparation, and use therefore
US6565897B2 (en) 1998-09-24 2003-05-20 Ozelle Pharmaceuticals, Inc. Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US20070154573A1 (en) 2005-12-27 2007-07-05 Juay Jamil Rashan Method of preparing and using a cold extract from the leaves of nerium oleander
US8034964B2 (en) 2007-08-06 2011-10-11 Ohio University Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin
US20100092585A1 (en) 2008-10-14 2010-04-15 Nerium Biotechnology, Inc. Plant extraction method and compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOULIKAS T ET AL: "RECENT CLINICAL TRIALS USING CISPLATIN, CARBOPLATIN AND THEIR COMBINATION CHEMOTHERAPY DRUGS (REVIEW)", ONCOLOGY REPORTS, SPANDIDOS PUBLICATIONS, GR, vol. 11, no. 3, 1 March 2004 (2004-03-01), pages 559 - 595, XP009053037, ISSN: 1021-335X *
GEHAN F.AGEORGE SL, THE JOURNAL OF PEDIATRICS, vol. 93, no. 1, 1978, pages 62 - 66
TAREK MEKHAIL ET AL: "Phase 1 trial of Anvirzel(TM) in patients with refractory solid tumors", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 24, no. 5, 5 April 2006 (2006-04-05), pages 423 - 427, XP019394425, ISSN: 1573-0646, DOI: 10.1007/S10637-006-7772-X *

Also Published As

Publication number Publication date
AU2012325819B2 (en) 2017-08-03
EP2768498A4 (de) 2015-06-17
AU2017254875A1 (en) 2017-11-23
US20130209579A1 (en) 2013-08-15
EP2768498B1 (de) 2020-03-04
RU2017136415A3 (de) 2021-02-08
IN2014KN00796A (de) 2015-10-02
MX365635B (es) 2019-06-10
WO2013059753A1 (en) 2013-04-25
RU2014120179A (ru) 2015-11-27
IL231987B (en) 2020-07-30
MX2019006685A (es) 2019-08-21
JP6255346B2 (ja) 2017-12-27
RU2017136415A (ru) 2019-02-08
CA2852274A1 (en) 2013-04-25
NZ623550A (en) 2016-06-24
BR112014009421A2 (pt) 2017-04-18
MX2014004527A (es) 2014-09-15
CN110269940A (zh) 2019-09-24
GT201400071A (es) 2015-09-17
CN104093405A (zh) 2014-10-08
US20190343908A1 (en) 2019-11-14
EP2768498A1 (de) 2014-08-27
IL275636A (en) 2020-08-31
AU2012325819A1 (en) 2014-04-24
JP2014530878A (ja) 2014-11-20
IL231987A0 (en) 2014-05-28
CA2852274C (en) 2019-08-06
AU2019203577A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
Li et al. Metformin induces cell cycle arrest, apoptosis and autophagy through ROS/JNK signaling pathway in human osteosarcoma
Banerjee et al. Oxidative stress triggered by naturally occurring flavone apigenin results in senescence and chemotherapeutic effect in human colorectal cancer cells
Liang et al. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair
US20190343908A1 (en) Therapeutic Combination for the Treatment of Cancer
Pang et al. Baicalin induces apoptosis and autophagy in human osteosarcoma cells by increasing ROS to inhibit PI3K/Akt/mTOR, ERK1/2 and β-catenin signaling pathways
Xie et al. Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response
Zhao et al. Effect of pristimerin on apoptosis through activation of ROS/endoplasmic reticulum (ER) stress-mediated noxa in colorectal cancer
Zhao et al. Total ginsenosides extract induce autophagic cell death in NSCLC cells through activation of endoplasmic reticulum stress
Chung et al. PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations
He et al. Schisandrin B suppresses gastric cancer cell growth and enhances the efficacy of chemotherapy drug 5-FU in vitro and in vivo
CN110433290A (zh) 隐丹参酮和TKI抑制剂联用在制备Ph+急性淋巴细胞白血病化疗药物中的应用
Jang et al. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway
Fan et al. Centipeda minima extract sensitizes lung cancer cells to DNA-crosslinking agents via targeting Fanconi anemia pathway
Putri et al. Bibenzyl analogue DS-1 inhibits MDM2-mediated p53 degradation and sensitizes apoptosis in lung cancer cells
Qu et al. Pomiferin targets SERCA, mTOR, and P-gp to induce autophagic cell death in apoptosis-resistant cancer cells, and reverses the MDR phenotype in cisplatin-resistant tumors in vivo
Lin et al. Acquired non-thermal plasma resistance mediates a shift towards aerobic glycolysis and ferroptotic cell death in melanoma
Chen et al. Guggulsterone induces apoptosis and inhibits lysosomal-dependent migration in human bladder cancer cells
Mi et al. Chinese medicine formula ‘Baipuhuang Keli’inhibits triple-negative breast cancer by hindering DNA damage repair via MAPK/ERK pathway
Liu et al. HTBPI, an active phenanthroindolizidine alkaloid, inhibits liver tumorigenesis by targeting Akt
Cui et al. Piperlongumine inhibits esophageal squamous cell carcinoma in vitro and in vivo by triggering NRF2/ROS/TXNIP/NLRP3-dependent pyroptosis
Yin et al. Combined Levo-tetrahydropalmatine and diphenyleneiodonium chloride enhances antitumor activity in hepatocellular carcinoma
Avelar Júnior et al. LyeTxI-b, a synthetic peptide derived from a spider venom, is highly active in triple-negative breast cancer cells and acts synergistically with cisplatin
CN114917219A (zh) 异荭草素联合顺铂在制备逆转肺癌耐药的药物中的应用
Nguyen et al. A new link between apoptosis induced by the metformin derivative HL156A and autophagy in oral squamous cell carcinoma
NZ623550B2 (en) Therapeutic combination for the treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 2768498

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210324